Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Preprint
Data sources: ZENODO
Zenodo
Claim

FcRn Inhibitor Combination with C5 Complement Blockade for Refractory MG

descriptionPublicationkeyboard_double_arrow_right Preprint Under curationPublisher:Zenodo
Authors: MedicOath Autonomous Discovery Engine;

doi: 10.5281/zenodo.19832424

FcRn Inhibitor Combination with C5 Complement Blockade for Refractory MG

Abstract

Dual targeting of FcRn (FCGRT, Open Targets score 0.59) and complement C5 (score 0.57) addresses both pathogenic antibody recycling and complement-mediated neuromuscular junction damage. ChEMBL compounds CHEMBL508564 and CHEMBL508411 target FCGRT, while existing drugs like eculizumab target C5.

Powered by OpenAIRE graph
Found an issue? Give us feedback